A 28-year-old woman from Mumbai with uncomplicated enteric fever (blood culture positive for Salmonella typhi, susceptible to all standard agents) is clinically stable and tolerating oral intake. Which is the preferred drug of choice for outpatient management?

Explanation

## Drug of Choice for Uncomplicated, Fully Susceptible Enteric Fever (Outpatient) ### Clinical Context & Selection Criteria **Key Point:** In **uncomplicated enteric fever** with **oral tolerance** and **outpatient management**, azithromycin is the **preferred drug of choice** — particularly in the Indian subcontinent where fluoroquinolone resistance (reduced susceptibility) is highly prevalent, even in isolates reported as "susceptible" by standard MIC breakpoints. ### Comparison of Agents in Susceptible Enteric Fever | Agent | Route | Intracellular Penetration | Duration | Oral Bioavailability | Preferred Setting | |---|---|---|---|---|---| | **Azithromycin** | Oral | Excellent (tissue/macrophage) | 5–7 days | ~40% (but high tissue levels) | **Uncomplicated, outpatient — preferred** | | Ciprofloxacin | Oral/IV | Excellent | 5–7 days | ~70% | Historically first-line; now limited by resistance | | Chloramphenicol | Oral/IV | Good | 7–14 days | ~75% | Obsolete; historical use only | | Ceftriaxone | IV only | Moderate | 7–14 days | N/A | Severe/complicated/hospitalized | ### Why Azithromycin is Preferred Here **High-Yield:** Azithromycin is the **current drug of choice for uncomplicated enteric fever in outpatient settings** (WHO 2011 guidelines; Harrison 21e; IAP guidelines) because: 1. **Excellent intracellular penetration** — achieves very high intracellular and tissue concentrations in macrophages where *Salmonella typhi* resides, despite moderate oral bioavailability 2. **Once-daily dosing** — 500 mg orally once daily for 5–7 days improves compliance in outpatient settings 3. **Resistance profile** — Fluoroquinolone resistance (including nalidixic acid–resistant strains and reduced ciprofloxacin susceptibility) is endemic in India and South Asia; azithromycin retains activity against these strains 4. **Comparable efficacy** — Clinical trials (including Parry et al.) demonstrate non-inferior defervescence and cure rates vs. fluoroquinolones in uncomplicated disease 5. **Safety** — Avoids fluoroquinolone-associated adverse effects (tendinopathy, QT prolongation, CNS effects) **Clinical Pearl:** The WHO and most current guidelines (Harrison 21e, Ch. 155; Oxford Handbook of Tropical Medicine) recommend **azithromycin as first-line oral therapy for uncomplicated typhoid fever**, with fluoroquinolones reserved for confirmed susceptible strains in low-resistance settings, and ceftriaxone for severe/complicated disease. ### Why Ciprofloxacin is No Longer the Default - Fluoroquinolone resistance in *S. typhi* from India is widespread; nalidixic acid resistance is a surrogate marker for reduced fluoroquinolone susceptibility - Even "susceptible" isolates by standard MIC may show clinical treatment failure with fluoroquinolones - Current Indian and WHO guidelines have moved azithromycin to first-line for uncomplicated outpatient typhoid ### Standard Dosing - **Azithromycin:** 500 mg orally once daily for 5–7 days - **Ceftriaxone:** 2 g IV once daily for 7–14 days (severe/complicated disease only) ### When to Use Alternatives - **Ceftriaxone:** Severe disease, complications (perforation, encephalopathy), or hospitalized patients - **Ciprofloxacin:** Only if fluoroquinolone susceptibility is confirmed AND local resistance rates are low - **Chloramphenicol:** Obsolete; not recommended due to bone marrow toxicity and superior alternatives **Mnemonic:** **AZO for Outpatient Typhoid** — **Az**ithromycin is the **O**utpatient drug of choice for uncomplicated enteric fever. [cite: Harrison 21e Ch 155; WHO Guidelines for the Treatment of Typhoid Fever, 2011; IAP Guidelines on Enteric Fever]